Bio AI Startup AMPLY Raises Seed Funding From Bluepoint Partners for Everyday Health Diagnostics

AMPLY, a bio AI startup focused on everyday health diagnostics, has raised seed funding from Bluepoint Partners. The investment amount and company valuation were not disclosed.

AMPLY’s core technology is a diagnostic platform called Triple-S, built on nanobio research from Yonsei University. The company has developed what it describes as the world’s first clip-type compression sampling method to detect low-concentration substances—a long-standing challenge in point-of-care diagnostics. When combined with its ultra-high-sensitivity bio AI diagnostic technology, A-cube, and deep learning–based quantitative analysis technology, Amp.Vision, the platform achieves reading accuracy of up to 99%.

Founded in July 2024, AMPLY has already generated revenue through its consumer brand Winti, which offers a range of everyday diagnostic products. The lineup includes LIV8, a nutrition-balance self-test kit; SkinCheck, a smart pH skin diagnostic kit; MSK, a male fertility diagnostic; and ASK, a post-intercourse self-test kit. The company also earned a Minister of SMEs and Startups award for co-developing a smart diaper–based baby health monitoring solution with Yuhan-Kimberly.

Founder and CEO Junmin Kim said AMPLY aims to make simple yet accurate health diagnostics a routine part of daily life.